Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22262872 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL2566030 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL27744339 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL19388060 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL10363351 | 0.84 | GAA (0.45) | SMN1; SMN2L3MBTL1GAAMAPK1MEN1 | |
| SCHEMBL4660065 | 0.84 | GAA (0.46) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL12506132 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL370828 | 0.82 | GAA (0.43) | SMN1; SMN2L3MBTL1GAAMAPK1MEN1 | |
| SCHEMBL370827 | 0.81 | GAA (0.43) | SMN1; SMN2L3MBTL1GAAMAPK1MMP8 | |
| SCHEMBL28464413 | 0.81 | KMT2A (0.50) | SMN1; SMN2GAAMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333985-B1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240262814-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4333985-A1 | MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117561251-A | Modulators of TREX1 | 星座制药公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-116547207-A | Antibacterial and antiviral molded body and master batch | 三井化学东赛璐株式会社 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022235725-A1 | MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220144712-A1 | SHAPED ARTIFICIAL POLYMER ARTICLES | BASF SE (DE) | 2022-05-12 | — | — | US | disclosed |
| US-9263870-B2 | System and method for applying an adhesive coated cable to a surface | COMMSCOPE TECHNOLOGIES LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140150971-A1 | System and Method for Applying an Adhesive Coated Cable to a Surface | ARRIS SOLUTIONS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | SMN1; SMN2 1624/4885L3MBTL1 4336/4885GAA 940/4885 |
| US-20240262814-A1 | MODULATORS OF TREX1 | CFTR, SLC10A1, CYP27A1 | SMN1; SMN2 222/4885L3MBTL1 3434/4885GAA 129/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | SMN1; SMN2 4479/4885L3MBTL1 3978/4885GAA 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.